Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.

MLA

Youn, Jin Won, et al. “Pembrolizumab plus GX-188E Therapeutic DNA Vaccine in Patients with HPV-16-Positive or HPV-18-Positive Advanced Cervical Cancer: Interim Results of a Single-Arm, Phase 2 Trial.” The Lancet. Oncology, vol. 21, no. 12, Dec. 2020, pp. 1653–60. EBSCOhost, https://doi.org/10.1016/S1470-2045(20)30486-1.

APA

Youn, J. W., Hur, S.-Y., Woo, J. W., Kim, Y.-M., Lim, M. C., Park, S. Y., Seo, S. S., No, J. H., Kim, B.-G., Lee, J.-K., Shin, S. J., Kim, K., Chaney, M. F., Choi, Y.-J., Suh, Y. S., Park, J. S., & Sung, Y. C. (2020). Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. The Lancet. Oncology, 21(12), 1653–1660. https://doi.org/10.1016/S1470-2045(20)30486-1

Chicago

Youn, Jin Won, Soo-Young Hur, Jung Won Woo, Yong-Man Kim, Myong Cheol Lim, Sang Yoon Park, Sang Soo Seo, et al. 2020. “Pembrolizumab plus GX-188E Therapeutic DNA Vaccine in Patients with HPV-16-Positive or HPV-18-Positive Advanced Cervical Cancer: Interim Results of a Single-Arm, Phase 2 Trial.” The Lancet. Oncology 21 (12): 1653–60. doi:10.1016/S1470-2045(20)30486-1.